Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
@edgarvlermamd
Apr 14, 2019 β€’ 19 tweets β€’ 29 min read β€’ Read on X
Scrolly
SGLT2 Inhibitors and Cardiorenal Outcomes in the February 2019 issue of @KidneyNews
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ kidneynews.org/kidney-news/is… ImageImageImage
EMPA-REG: Empagliflozin, CV outcomes and mortality in Type 2 Diabetes ca. 2015 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ nejm.org/doi/pdf/10.105… ImageImage
CANVAS: Canagliflozin and CV & Renal events in Type 2 Diabetes ca. 2017 from @NEJM
#VisualAbstract by @kidney_boy
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ nejm.org/doi/pdf/10.105… ImageImage
CV and Renal Outcomes With Canagliflozin According to Baseline Kidney Function ca. 2018 from @CircAHA
#VisualAbstract by @brendonneuen
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ ahajournals.org/doi/pdf/10.116… ImageImage
Effect of SGLT2 inhibitors on CV, renal and safety outcomes in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis ca. 2019
#VisualAbstract by @brendonneuen
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ ncbi.nlm.nih.gov/m/pubmed/30697… ImageImage
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials ca. 2018 from @TheLancet
#VisualAbstract by @divyaa24
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ ncbi.nlm.nih.gov/m/pubmed/29937… Image
MT @Nephro_Sparks CREDENCE: Canagliflozin reduced the risk of the primary outcome of ESKD, doubling of SCr, or renal or CV death by 30%‼️
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls ImageImage
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM
#VisualAbstract by @brendonneuen
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ nejm.org/doi/pdf/10.105… ImageImage
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #NephJC
#VisualAbstract by @brendonneuen
#ISNWCN πŸ‡¦πŸ‡ΊπŸ¦˜ #Nephpearls
πŸ‘‰πŸΌ nejm.org/doi/pdf/10.105… ImageImageImageImage
CREDENCE: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Study Rationale, Design, and Baseline Characteristics ca. 2017 from @AmJNephrol #Nephpearls
πŸ‘‰πŸΌ karger.com/Article/Pdf/48… ImageImageImageImage
Ongoing trials of SGLT2 Inhibitors of interest to the Nephrology Community ca. 2019
Table by @drlovygaur #Nephpearls #NephJC Image
CREDENCE: Canagliflozin reduces the risk of kidney failure or death due to CV or kidney disease by 30% compared to current standard of care ca. 2019 from @NEJM #Nephpearls
πŸ‘‰πŸΌ nejm.org/doi/pdf/10.105… ImageImageImage
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD ca. 2019 from @AJKDonline #Nephpearls
πŸ‘‰πŸΌ ajkd.org/article/S0272-… ImageImage
Class effects of SGLT2 inhibitors on cardiorenal outcomes ca. 2019 #Cardiorenal #Nephpearls
πŸ‘‰πŸΌ cardiab.biomedcentral.com/articles/10.11… ImageImageImageImage
SGLT2 Inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin) are recommended to lower risk of heart failure hospitalization‼️
#ESCcongress πŸ‡«πŸ‡· #Nephpearls #Cardiorenal
πŸ‘‰πŸΌ escardio.org/Guidelines/Cli… ImageImage
SGLT2 Inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin) are recommended to lower risk of heart failure hospitalization‼️
#ESCcongress πŸ‡«πŸ‡· #Nephpearls #Cardiorenal
πŸ‘‰πŸΌ escardio.org/Guidelines/Cli… ImageImageImage
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis ca. 2019 from @TheLancetEndo @brendonneuen @jardine_meg @VladoPerkovic #Nephpearls
πŸ‘‰πŸΌ thelancet.com/journals/landi… ImageImage
Diabetes and Kidney Disease: SGLT2 Inhibitors by @ChristosArgyrop in the August 2019 issue of @KidneyNews #Nephpearls
πŸ‘‰πŸΌ asn-online.org/publications/k… ImageImageImageImage
Emerging glucose-lowering therapies ca. 2019 from @DrMattGB @bmj_latest #Nephpearls
πŸ‘‰πŸΌ ncbi.nlm.nih.gov/m/pubmed/31551… ImageImageImageImage

β€’ β€’ β€’

Missing some Tweet in this thread? You can try to force a refresh
γ€€

Keep Current with Edgar V. Lerma πŸ‡΅πŸ‡­

Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @edgarvlermamd

Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Feb 26, 2022
Advancing Evidence-Based Care in Diabetes and CKD
#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls

πŸ‘‰ kdigo.org/wp-content/upl…
Holistic approach for improving outcomes in patients with Diabetes and CKD
#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls
Glucose-lowering agents in Type 2 Diabetes (T2D) and CKD: Indications and dose adjustments
#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls
Read 9 tweets
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Feb 26, 2022
.@goKDIGO Glomerular Diseases Guideline: Reflections on a Decade of Progress with @adrianliew8 @ReichHeather @Dr_KeishaGibson
#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls

πŸ‘‰ kdigo.org/wp-content/upl…
IgA Nephropathy: A 1st step is in treating IgA Nephropathy is assessing "prognosis" based on data available at the time of biopsy

@goKDIGO suggest using the "prediction tool" that was derived from the largest & most geographically diverse cohort to date

#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls
IgA Nephropathy: The @goKDIGO treatment algorithm recommends consideration of use of corticosteroids in patients with "persistent proteinuria >1g/day" if the risk/benefit profile is favorable

πŸ“Œ A GFR of 30 is considered a threshold for treatment

#ISNWCN πŸ‡²πŸ‡Ύ #Nephpearls
Read 13 tweets
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Feb 23, 2022
First clinical-grade porcine πŸ– kidney xenotransplant using a human decedent model ca. 2022 from @amjtransplant #NephJC #Nephpearls

#VisualAbstract by @NamrataYParikh

πŸ‘‰πŸΌ pubmed.ncbi.nlm.nih.gov/35049121/ Image
Attitudes to Clinical Pig Kidney Xenotransplantation among Medical Providers and Patients ca. 2020 from @ASNKidney360 #Nephpearls

kidney360.asnjournals.org/content/1/7/657 ImageImage
Paving the Path toward Porcine Organs for Transplantation ca. 2017 from @NEJM #NephJC #Nephpearls

nejm.org/doi/full/10.10… ImageImage
Read 4 tweets
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Jan 30, 2022
Nephrolithiasis 101: When to order a 24-hour urine collection #Nephpearls

Multiple or metabolically active stones (stones that increase in size/ number w/in a year)

Children

Demographic groups not typically prone to stone formation

Stones other than those containing calcium ImageImage
Interpretation of urine chemistries to identify lithogenic risk factors and assess the contribution of diet to the formation of kidney stones ca. 2016 from @ravineja #Nephpearls

sciencedirect.com/science/articl… Image
Neglected analytes in the 24 hour urine: ammonium and sulfate ca. 2021 from @CO_Neph_Hype @ravineja #Nephpearls

πŸ‘‰ pubmed.ncbi.nlm.nih.gov/34798636/ ImageImageImageImage
Read 4 tweets
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Jan 26, 2022
PREDNOS 2: Evaluation of Daily Low-Dose Prednisolone During URTI to Prevent Relapse in Children w/ Relapsing Steroid-Sensitive Nephrotic Syndrome ca, 2022 from @JAMAPediatrics #NephJC #IPNAJC #Nephpearls

#VisualAbstract by @drM_sudha

jamanetwork.com/journals/jamap…
Low-dose versus conventional-dose prednisolone for nephrotic syndrome relapses: a randomized controlled non-inferiority trial ca. 2022 from @Ped_Neph #NephJC #IPNAJC #Nephpearls

#VisualAbstract by @md_abdulqader83

link.springer.com/article/10.100…
PREDNOS: Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome ca. 2019 from @bmj_latest #NephJC #IPNAJC #Nephpearls

#VisualAbstract by @jbda19

pubmed.ncbi.nlm.nih.gov/31156083/
Read 5 tweets
Edgar V. Lerma πŸ‡΅πŸ‡­ Profile picture
Nov 17, 2021
Clinical Practice Guideline for the Management of Glomerular Diseases ca. 2021 from @goKDIGO #NephJC #Nephpearls
#VisualGraphics by @michaelturk6

Executive Summary pubmed.ncbi.nlm.nih.gov/34556300/
Full Guideline pubmed.ncbi.nlm.nih.gov/34556256/
The spectrum of glomerular diseases from @neilturn #NephJC #Nephpearls

πŸ‘‰ global.oup.com/academic/produ…
Nephrotic range proteinuria does "not always" mean nephrotic syndrome #NephJC #Nephpearls

πŸ‘‰ pubmed.ncbi.nlm.nih.gov/34556256/
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(